FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2343711297> ?p ?o ?g. }

• W2343711297 abstract "Abstract Hematopoietic stem and progenitor cells (HSPCs) are exposed to a variety of intrinsic and extrinsic factors regulating all processes needed during development, and for successful engraftment after transplantation. In order to decipher the molecular pathways that may promote engraftment of HSPCs after marrow transplantation, we performed a competitive transplantation screen using chemical genetics in zebrafish. Green fluorescent protein-labeled kidney marrow cells (equivalent to mammalian bone marrow cells) were treated ex vivo with single compounds of a chemical library of known biologically active compounds, and administered by retro-orbital venous injection to lethally irradiated recipient zebrafish. About 500 chemicals were screened. Untreated kidney marrow cells labeled with a red fluorescent protein were used as competitors. Imaging-based assessment of short-term engraftment demonstrated that 1,2-Didecanoylglycerol, a membrane permeable but non-physiologic analogue of diacylglycerol (DAG), significantly improved engraftment compared to competitor cells. Follow-up by FACS analysis showed a 3.5 fold increase of long-term repopulating units after DAG treatment. To interrogate whether DAG treatment not only affects HSPCs under transplant conditions, but also during normal embryonic development, we treated zebrafish embryos within the time window of HSC formation in the dorsal aorta. DAG treatment increased expression of the HSPC markers Runx1 and c-myb in the AGM (Aorto-Gonad-Mesonephros). Treatment after HSC specification also led to an upregulation of HSPC markers in the caudal hematopoietic tissue (equivalent to fetal liver in mammals). These data suggest that DAG affects not only HSC formation, but also migration and engraftment of HSPCs as hematopoiesis transitions from the AGM to the CHT during development. To determine whether HSPCs respond to DAG in a cell autonomous manner, and to identify the underlying molecular mechanism, we treated human CD34+ cells from umbilical cord blood with DAG and performed RNA-seq analysis. Ingenuity Pathway Analysis of the 395 differentially expressed genes (q-value < 0.05) implicated the MAP kinase pathway as an upstream regulator. Human Phosphokinase array analysis of treated CD34+ showed ERK 1/2 activation. DAG is known to activate Protein Kinase C (PKC) with subsequent Raf kinase phosphorylation, which has the potential to activate ERK. Co-treatment of CD34+ cells with DAG and the ERK inhibitor PD98059 blocked upregulation of downstream ERK-targets (e.g. AREG, CSF2, EGR1, HMOX, SERPINE1, DUSP4, DUSP6), whereas the PI3K family inhibitor LY294002 and the p38 MAP kinase inhibitor SB202190 did not alter the effect of DAG on expression of these genes. This demonstrates that DAG activates ERK and its downstream targets. Our competitive marrow transplantation-based chemical screen has led to the discovery of 1,2-Didecanoylglycerol as a novel modulator of HSPC development and engraftment after transplantation. This discovery may be of clinical relevance to marrow or cord blood hematopoietic stem cell transplantation. Disclosures: Zon: FATE Therapeutics, Inc: Consultancy, Equity Ownership, Founder Other, Membership on an entity’s Board of Directors or advisory committees, Patents & Royalties; Stemgent, Inc: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Stocks, Stocks Other; Scholar Rock: Consultancy, Equity Ownership, Founder, Founder Other, Membership on an entity’s Board of Directors or advisory committees, Patents & Royalties." @default.
• W2343711297 created "2016-06-24" @default.
• W2343711297 creator A5054432692 @default.
• W2343711297 creator A5059372936 @default.
• W2343711297 creator A5060947246 @default.
• W2343711297 creator A5068049269 @default.
• W2343711297 creator A5086372369 @default.
• W2343711297 date "2013-11-15" @default.
• W2343711297 modified "2023-09-28" @default.
• W2343711297 title "Diacylglycerol Enhances Hematopoietic Stem/Progenitor Cell Development and Engraftment Via MAP Kinase Activation" @default.
• W2343711297 doi "https://doi.org/10.1182/blood.v122.21.174.174" @default.
• W2343711297 hasPublicationYear "2013" @default.
• W2343711297 type Work @default.
• W2343711297 sameAs 2343711297 @default.
• W2343711297 citedByCount "0" @default.
• W2343711297 crossrefType "journal-article" @default.
• W2343711297 hasAuthorship W2343711297A5054432692 @default.
• W2343711297 hasAuthorship W2343711297A5059372936 @default.
• W2343711297 hasAuthorship W2343711297A5060947246 @default.
• W2343711297 hasAuthorship W2343711297A5068049269 @default.
• W2343711297 hasAuthorship W2343711297A5086372369 @default.
• W2343711297 hasConcept C104317684 @default.
• W2343711297 hasConcept C109159458 @default.
• W2343711297 hasConcept C126322002 @default.
• W2343711297 hasConcept C201750760 @default.
• W2343711297 hasConcept C203014093 @default.
• W2343711297 hasConcept C207001950 @default.
• W2343711297 hasConcept C26291073 @default.
• W2343711297 hasConcept C2776878037 @default.
• W2343711297 hasConcept C2778086970 @default.
• W2343711297 hasConcept C2780007613 @default.
• W2343711297 hasConcept C28328180 @default.
• W2343711297 hasConcept C2911091166 @default.
• W2343711297 hasConcept C502942594 @default.
• W2343711297 hasConcept C54355233 @default.
• W2343711297 hasConcept C71924100 @default.
• W2343711297 hasConcept C86803240 @default.
• W2343711297 hasConcept C95444343 @default.
• W2343711297 hasConceptScore W2343711297C104317684 @default.
• W2343711297 hasConceptScore W2343711297C109159458 @default.
• W2343711297 hasConceptScore W2343711297C126322002 @default.
• W2343711297 hasConceptScore W2343711297C201750760 @default.
• W2343711297 hasConceptScore W2343711297C203014093 @default.
• W2343711297 hasConceptScore W2343711297C207001950 @default.
• W2343711297 hasConceptScore W2343711297C26291073 @default.
• W2343711297 hasConceptScore W2343711297C2776878037 @default.
• W2343711297 hasConceptScore W2343711297C2778086970 @default.
• W2343711297 hasConceptScore W2343711297C2780007613 @default.
• W2343711297 hasConceptScore W2343711297C28328180 @default.
• W2343711297 hasConceptScore W2343711297C2911091166 @default.
• W2343711297 hasConceptScore W2343711297C502942594 @default.
• W2343711297 hasConceptScore W2343711297C54355233 @default.
• W2343711297 hasConceptScore W2343711297C71924100 @default.
• W2343711297 hasConceptScore W2343711297C86803240 @default.
• W2343711297 hasConceptScore W2343711297C95444343 @default.
• W2343711297 hasLocation W23437112971 @default.
• W2343711297 hasOpenAccess W2343711297 @default.
• W2343711297 hasPrimaryLocation W23437112971 @default.
• W2343711297 hasRelatedWork W1966205399 @default.
• W2343711297 hasRelatedWork W2070634808 @default.
• W2343711297 hasRelatedWork W2088381442 @default.
• W2343711297 hasRelatedWork W2149050321 @default.
• W2343711297 hasRelatedWork W2519460404 @default.
• W2343711297 hasRelatedWork W2530895375 @default.
• W2343711297 hasRelatedWork W2552017408 @default.
• W2343711297 hasRelatedWork W2563438165 @default.
• W2343711297 hasRelatedWork W2586118257 @default.
• W2343711297 hasRelatedWork W2593114235 @default.
• W2343711297 hasRelatedWork W2593240086 @default.
• W2343711297 hasRelatedWork W2610405560 @default.
• W2343711297 hasRelatedWork W2763352299 @default.
• W2343711297 hasRelatedWork W2961874660 @default.
• W2343711297 hasRelatedWork W2979756176 @default.
• W2343711297 hasRelatedWork W3043240656 @default.
• W2343711297 hasRelatedWork W3044360224 @default.
• W2343711297 hasRelatedWork W3095933316 @default.
• W2343711297 hasRelatedWork W3133146426 @default.
• W2343711297 hasRelatedWork W3198216659 @default.
• W2343711297 isParatext "false" @default.
• W2343711297 isRetracted "false" @default.
• W2343711297 magId "2343711297" @default.
• W2343711297 workType "article" @default.